5月20日,三生制药(01530)早盘一度暴涨40%,股价最高触及22港元,逼近历史前高。截至发稿,涨幅达36.28%,报19.76港元,成交额31.93亿港元。此次暴涨源于公司与辉瑞达成合作,辉瑞获得PD-1/VEGF双特异性抗体SSGJ-707的全球(除中国内地)独家开发权。三生制药将获12.5亿美元首付款及最高48亿美元里程碑付款,并享有净销售额提成。同时,辉瑞将以30日成交量加权平均价认购...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.